

## DAFTAR PUSTAKA

- Abe M., Hiasa Y., and Onji M, 2013. T Helper 17 Cells in Autoimmune Liver Diseases. *Clinical and Developmental Immunology*, Volume 2013, Article ID 607073, 6 pages.
- Aggarwal B. B., Surh Y. J., Shishodia S. 2007. *The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease*. 1<sup>st</sup> Ed., Springer, India, p. 436-437
- Alrawaiq N. S., and Abdullah A, 2014. A Review of Antioxidant Polyphenol Curcumin and its Role in Detoxification. *International Journal of PharmTech Research*, 6 (1), 280-89.
- ATSDR, 2005. *Toxicological Profile for Carbon Tetrachloride* (Update). Atlanta, GA: U.S. Department of Public Health and Human Services, Public Health Service. n.p.
- Baker Muntaha, 2010. *Detection of IL-17 Producing Cells in Liver Biopsies of Patients with Autoimmune Hepatitis*. Bachelor Project. Institute of Liver Studies, King's College Hospital, London, UK. p.5-12.
- Balanescu P, Ladaru A, Voiosu T, Nicolau A, Ene W, and Balanescu E. 2012. Th17 and IL-17 Immunity in Chronic Hepatitis C. *Infection Journal Internal Medicine*: p.13-18.
- Bataller, R. and Brenner, D. 2005. Liver fibrosis. *Journal of Clinical Investigation*, 115(2), pp.209-218
- Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J., Saracco, G., Adams, L., Charatcharoenwitthaya, P., Topping, J., Bugianesi, E., Day, C. and George, J. (2011). The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. *Hepatology*, 54(4), pp.1208-1216.

Burgos-Moron E., Calderon-Montano J. M., Salvador J., Robles A., Lopez-Lazaro M. The darkside of curcumin. *International Journal of Cancer*. 2010. 126: 1771-1775

Carter, Michael. 2013. *Liver disease a major cause of illness and death across the EU: action needed to save lives*

Chen, A. and Zheng, S., 2008. Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF- $\kappa$ B and ERK signalling. *British Journal of Pharmacology*, 153(3), pp.557-567.

Dong C. Th17 cells in development: an updated view of their molecular identify and genetic programming. *Nature Review Immunology*. 2008. 8: 337-348.

Du W.J., Zhen J., Zeng Z., Zheng Z., Xu Y., Qin L., and Chen S., 2013. Expression of Interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. *Diagnostic Pathology*, 8(1), p.40.

Fitz JG. *Approach to the Patient with Suspected Liver Disease*, Current Diagnosis & Treatment in Gastroenterology, 2nd Edition. Friedman SLM, Kenneth R.; Grendell, James H., McGraw-Hill; 2003.

Friedman, S. (2010). Evolving challenges in hepatic fibrosis. *Nat Rev Gastroenterol Hepatol*, 7(8), pp.425-436.

Fu Y., Zheng S., Lin J., Ryerse J., Chen A. *Curcumin Protects the Rat Liver from CCl<sub>4</sub>-Caused Injury and Fibrogenesis by Attenuating Oxidative Stress and Suppressing Inflammation*. *Molecular Pharmacology*. 2008. 73(2): 399-409.

Gandhi C. R., Pinzani M. 2015. *Stellate Cells in Health and Disease*. 1st Ed., Academic Press, London, p. 41-55.

Goel A., Kunnumakkara A.B., and Aggarwal B.B., 2008. Curcumin as "Curcumin": From kitchen to clinic. *Biochemical pharmacology* 75, 787-09.

- Hammerich, L., Heymann, F. and Tacke, F. (2011). Role of IL-17 and Th17 Cells in Liver Diseases. *Clinical and Developmental Immunology*, 2011, pp.1-12.
- Henderson N. C., Iredale J. P. Liver Fibrosis: cellular mechanisms of progression and resolution. *Clinical Science*. 2007. 112(5): 265-280.
- Irving, G.R., Karmokar, A., Berry, D.P., Brown, K. and Steward, W.P., 2011. Curcumin: the potential for efficacy in gastrointestinal diseases. *Best Practice & Research Clinical Gastroenterology*, 25(4), pp.519-534.
- Ismail MH.2011. Reversal of Liver Fibrosis: A Review. *Liver Biopsy in Modern Medicine*.
- Junieva PN. 2006. *Pengaruh Pemberian Ekstrak Meniran (Phyllanthus sp.) terhadap Gambaran Mikroskopik Paru Tikus Wistar yang Diinduksi Karbon Tetraklorida*. Artikel Ilmiah. Fakultas kedokteran. Universitas Diponegoro. Semarang.
- Lafdil, F., Miller, A., Ki, S. and Gao, B. (2010). Th17 cells and their associated cytokines in liver diseases. *Cell Mol Immunol*, 7(4), pp.250-254.
- Li, L., Hu, Z., Li, W., Hu, M., Ran, J., Chen, P. and Sun, Q. (2012). Establishment of a Standardized Liver Fibrosis Model with Different Pathological Stages in Rats. *Gastroenterology Research and Practice*, 2012, pp.1-6.
- Lin Xie a,b,d, Xiao-Kang Li a., Naoko Funeshima-Fuji a, Hiromitsu Kimura a, Yoh Matsumoto c, Yoshitaka Isaka b, Shiro Takahara. 2009. *Amelioration of Experimental Autoimmune Encephalomyelitis by Curcumin Treatment Through Inhibition of IL-17 Production*. pp.575-581.
- Marra F., Tacke F. Roles for Chemokine in Liver Disease. *Gastroenterology*. 2014. 147(3): 577-594
- Meng F., Wang K., Aoyama T., Grivennikov S., Paik Y., Scholten D., et al, 2012. Interleukin-17 Signaling in Inflammatory, Kupffer Cells, and Hepatic Stellate

Cells Exacerbates Liver Fibrosis in Mice. *Gastroenterology*, 143(3), pp.765-776.e3.

Mills KHG. 2008. Induction, function and regulation of IL-17-producing T cells. *European Journal Immunology*. 38: 2636–2649.

MinJung Park, SuJin Moon, SungHee Lee, EunJi Yang, JunKi Min, SeokGoo Cho, ChulWoo Yang, SungHwan Park, HoYoun Kim, and MiLa Cho. 2013. *Curcumin Attenuates Acute Graft-versus-host Disease Severity via In Vivo Regulations on Th 1, Th 17, and T regulation*. PMID: PMC3688629

Moseley TA, Haudenschild DR, Rose L, Reddi AH. 2003. Interleukin-17 family and IL-17 receptors. *Cytokine & Growth Factor ELSEVIER journal*.

Musthofiyah H. 2008. *Pengaruh Pemberian Buah Pepaya (Carica papaya) terhadap Kadar Enzim Transaminase got-gpt dan Gambaran Histologi Hepar Mencit (Mus Musculus) yang Diinduksi Karbon Tetraklorida (CCl<sub>4</sub>)*. Skripsi. Tidak diterbitkan. Fakultas Sains dan Teknologi, Universitas Islam Negeri Malang.

Park, H., Li, Z., Yang, X., Chang, S., Nurieva, R., Wang, Y., Wang, Y., Hood, L., Zhu, Z., Tian, Q. and Dong, C. (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *Nat Immunol*, 6(11), pp.1133-1141.

Poynard T., Lebray P., Ingiliz P., Varaut A., Varsat B., Ngo, Y., *et al*, 2011. *Prevalence of Liver Fibrosis and Risk Factors in a General Population using Non-Invasive Biomarkers (FibroTest)*. *BMC gastroenterology*, 10(1), p.40. Perhimpunan Peneliti Hati Indonesia [Internet]. Jakarta: Perhimpunan Peneliti Hati Indonesia: 2013.

Ramon B., Daud A.B., 2005. Liver fibrosis. *The Journal of Clinical Investigation*, 115:209-18.

Rivera Espinoza Y., and Muriel P., 2009. Pharmacological actions of curcumin in liver diseases or damage. *Liver International*, 29(10), pp.1457-1466.

- Rockey, D. (2008). Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease. *Clinics in Liver Disease*, 12(4), pp.939-962.
- Romagnani, S. 2008. Human Th17 cells. *Arthritis Research & Therapy*, 10(2), p.206.
- Simanjuntak P. Studi Kimia dan Farmakologi Tanaman Kunyit (*Curcuma longa* L) sebagai Tumbuhan Obat Serbaguna. *Jurnal Ilmu Pertanian "Agrium"*. 2012. 17(2): 103-107.
- Tan z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, dkk. 2013. IL-17A Plays a Critical Role in the Pathogenesis of Liver Fibrosis through Hepatic Stellate Cell Activation. *The Journal of Immunology*. 191:1835-1844; doi: 10.4049/jimmunol.1203013
- Wang L, Chen S, and Xu K. 2010. IL-17 expression is correlated with hepatitis B-related liver diseases and fibrosis. *International Journal of Molecular Medicine*.
- Wang P., Koyama Y., Liu X., Xu J., Ma H. Y., Liang S., Kim I. H., Brenner D. A., Kisseleva T. Promising Therapy Candidates for Liver Fibrosis. *National Center for Biotechnology Information*. 2016. 7(47): 1-9
- Wijayati, R., 2002. Analisis Penggunaan Hepatoprotektor Pada Terapi Hepatitis Di Instalasi Rawat Inap Rumah Sakit Angkatan Laut Dr. Ramelan Surabaya
- Witowski J, Ksiazek K, and Jorres A. 2003. Interleukin-17: a mediator of inflammatory responses. *Cellular and Molecular Life Sciences*. p. 567-579
- Zhang, F. Zili Zhang, Li Chen, Desong Kong, Xiaoping Zhang, Chunfeng Lu, Yin Lu, and Shizhong Zheng. 2014. Curcumin attenuates angiogenesis in liver fibrosis and inhibits angiogenic properties of hepatic stellate cells. *Journal of Cellular and Molecular Medicine*.
- Zhang J., Zhang Z., Lin F., Zou Z., Xu R., Jin L., et al, 2009. Interleukin-17-producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B. *Hepatology*, 51(1), pp.81-91

Zheng S., Chen A. Activation of PPAR $\gamma$  is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cell in vitro. *Biochemical Journal*. 2004. 384(1): 149-157.

Ziol, M., Handra-Luca, A., Kettaneh, A., Christidis, C., Mal, F., Kazemi, F., de Lédighen, V., Marcellin, P., Dhumeaux, D., Trinchet, J.C. and Beaugrand, M., 2005. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology*, 41(1), pp.48-54.

